413 related articles for article (PubMed ID: 22951238)
21. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
22. Patient compliance with MAO inhibitor therapy.
Walker JI; Davidson J; Zung WW
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):78-80. PubMed ID: 6735998
[TBL] [Abstract][Full Text] [Related]
23. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
Kennedy SH
J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
25. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
26. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
27. Monoamine oxidase inhibitors.
Lippmann S
Am Fam Physician; 1986 Jul; 34(1):113-9. PubMed ID: 3728254
[TBL] [Abstract][Full Text] [Related]
28. [Irreversible, non-selective monoamine oxidase inhibitors].
Castberg I; Spigset O
Tidsskr Nor Laegeforen; 2009 Apr; 129(8):746-8. PubMed ID: 19373300
[TBL] [Abstract][Full Text] [Related]
29. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
[TBL] [Abstract][Full Text] [Related]
30. Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.
Chamberlain SR; Baldwin DS
CNS Drugs; 2021 Jul; 35(7):703-716. PubMed ID: 34240393
[TBL] [Abstract][Full Text] [Related]
31. Selegiline transdermal system: current awareness and promise.
Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
[TBL] [Abstract][Full Text] [Related]
32. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
33. Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up?
Sweet RA; Brown EJ; Heimberg RG; Ciafre L; Scanga DM; Cornelius JR; Dube S; Forsyth KM; Holt CS
J Clin Psychiatry; 1995 May; 56(5):196-201. PubMed ID: 7737959
[TBL] [Abstract][Full Text] [Related]
34. The use of MAOIs in primary care.
Culpepper L
J Clin Psychiatry; 2012 May; 73(5):e19. PubMed ID: 22697202
[TBL] [Abstract][Full Text] [Related]
35. Management of depression in the elderly.
Williams GO
Prim Care; 1989 Jun; 16(2):451-74. PubMed ID: 2664841
[TBL] [Abstract][Full Text] [Related]
36. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
37. Monoamine oxidase inhibitors. An update on drug interactions.
Livingston MG; Livingston HM
Drug Saf; 1996 Apr; 14(4):219-27. PubMed ID: 8713690
[TBL] [Abstract][Full Text] [Related]
38. Monoamine oxidase inhibitors: reversible and irreversible.
Rudorfer MV
Psychopharmacol Bull; 1992; 28(1):45-57. PubMed ID: 1609042
[TBL] [Abstract][Full Text] [Related]
39. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
Park SH; Wackernah RC; Stimmel GL
J Pharm Pract; 2014 Feb; 27(1):71-8. PubMed ID: 24153222
[TBL] [Abstract][Full Text] [Related]
40. Practical aspects of MAO inhibitor therapy.
Davidson J; Zung WW; Walker JI
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):81-4. PubMed ID: 6735999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
